FIELD: pharmaceuticals.
SUBSTANCE: invention relates to piperidine urea derivatives, Claim 1, and to their pharmaceutically acceptable salts. Invention also relates to drugs which inhibit the activity of Tankyrases (TANKs) and poly(ADP-ribose)polymerase PARP-1, based on these compounds.
EFFECT: new compounds have been obtained that can be used in medicine for the treatment of diseases such as malignant neoplasm, cardiovascular diseases, central nervous system lesions and various forms of inflammation.
2 cl, 3 tbl, 37 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OXOQUINAZOLINYL-BUTANAMIDE DERIVATIVES | 2014 |
|
RU2669393C2 |
| 3-AMINOCYCLOPENTANCARBOXAMIDE DERIVATIVES | 2013 |
|
RU2641913C2 |
| QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | 2013 |
|
RU2650107C2 |
| BENZOXAZEPINE PI3 INHIBITORS AND METHODS OF USE | 2010 |
|
RU2654068C1 |
| TLR7/8 ANTAGONISTS AND THEIR APPLICATION | 2017 |
|
RU2758686C2 |
| DERIVATIVES OF INDOLIN-2-SHE AS INHIBITORS OF PROTEINKINAS | 2013 |
|
RU2627706C2 |
| QUINOLINE-2 DERIVATIVES AS C-KIT KINASE INHIBITORS | 2016 |
|
RU2754858C2 |
| 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | 2020 |
|
RU2822388C2 |
| CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DESTRUCTION OF ANDROGEN RECEPTORS AND USE THEREOF | 2020 |
|
RU2825000C2 |
| ISOINDOLINE COMPOUND, PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION AND THEIR USE | 2019 |
|
RU2813232C2 |
